Serum drug levels of biologic agents in the management of rheumatoid arthritis and spondyloarthritis: a systematic review

[1]  J. Hazes,et al.  Cost-effectiveness of Biological Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis: Implications for Clinical Practice , 2017, The Journal of Rheumatology.

[2]  V. Strand,et al.  Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review , 2017, BioDrugs.

[3]  R. Landewé,et al.  Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis , 2017, RMD Open.

[4]  A. Barton,et al.  High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort , 2016, Annals of the rheumatic diseases.

[5]  X. Mariette,et al.  Immunogenicity of tocilizumab in patients with rheumatoid arthritis. , 2017, Joint, bone, spine : revue du rhumatisme.

[6]  J. M. García Ruiz de Morales,et al.  [Anti-tumor necrosis factor drug therapy: The usefulness of monitoring drug levels and anti-drug antibodies in clinical practice]. , 2016, Medicina clinica.

[7]  D. Pascual‐Salcedo,et al.  [Anti-tumor necrosis factor drug therapy: The usefulness of monitoring drug levels and anti-drug antibodies in clinical practice]. , 2016 .

[8]  H. Bliddal,et al.  Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study , 2016, PloS one.

[9]  P. Sarzi-Puttini,et al.  Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab , 2016, Biologics : targets & therapy.

[10]  S. Palmer,et al.  Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. , 2016, Health technology assessment.

[11]  T. Hsieh,et al.  Concise Report , 2022 .

[12]  E. Martı́n-Mola,et al.  Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations: A Cohort Study in Clinical Practice Conditions , 2015, Front. Med..

[13]  F. Vives,et al.  An Examination of the Mechanisms Involved in Secondary Clinical Failure to Adalimumab or Etanercept in Inflammatory Arthropathies , 2015, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[14]  M. Nurmohamed,et al.  Key findings towards optimising adalimumab treatment: the concentration-effect curve. , 2015, Annals of the rheumatic diseases.

[15]  G. Burmester,et al.  Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial , 2014, Annals of the rheumatic diseases.

[16]  W. Hung,et al.  Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis , 2014, Annals of the rheumatic diseases.

[17]  W. Lems,et al.  Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects , 2013, Annals of the rheumatic diseases.

[18]  G. Wolbink,et al.  Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up , 2013, Annals of the rheumatic diseases.

[19]  J. Rosas,et al.  Clinical relevance of monitoring serum levels of adalimumab in patients with rheumatoid arthritis in daily practice. , 2014, Clinical and experimental rheumatology.

[20]  M. Nurmohamed,et al.  Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice , 2014, Annals of the rheumatic diseases.

[21]  D. Baeten,et al.  Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation , 2014, Arthritis Research & Therapy.

[22]  R. Ionescu,et al.  Monitoring Drug and Antidrug Levels: A Rational Approach in Rheumatoid Arthritis Patients Treated with Biologic Agents Who Experience Inadequate Response While Being on a Stable Biologic Treatment , 2014, BioMed research international.

[23]  Laure Gossec,et al.  Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis , 2014, Annals of the rheumatic diseases.

[24]  J. Demengeot,et al.  A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies , 2013, Annals of the rheumatic diseases.

[25]  B. Dijkmans,et al.  Patients non-responding to etanercept obtain lower etanercept concentrations compared to responding patients , 2013 .

[26]  P. Goupille,et al.  Therapeutic Drug Monitoring of Infliximab in Spondyloarthritis: An Observational Open-Label Study , 2011, Therapeutic drug monitoring.

[27]  Hervé Watier,et al.  Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases , 2011, Arthritis research & therapy.

[28]  B. Dijkmans,et al.  Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. , 2011, JAMA.

[29]  P. Goupille,et al.  Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis , 2009, Arthritis research & therapy.

[30]  N. Miyasaka,et al.  Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study , 2009, Modern rheumatology.

[31]  M. Dougados,et al.  Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study. , 2009, Arthritis and rheumatism.

[32]  K. Bendtzen,et al.  Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. , 2006, Arthritis and rheumatism.

[33]  B. Dijkmans,et al.  Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[34]  E. Keystone,et al.  The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. , 2002, Arthritis and rheumatism.

[35]  Huub Schellekens,et al.  Bioequivalence and the immunogenicity of biopharmaceuticals , 2002, Nature Reviews Drug Discovery.